Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

for expanded use in Crohn’s disease (CD). The CHMP has recommended Omvoh to treat adults with moderately to severely active CD, who have had an inadequate response with, lost response to ...

Omvoh’s approval as a treatment for Crohn’s disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had ...

highlighting Omvoh’s efficacy in CD through their commercial exhibits and an industry-sponsored symposium titled: ‘Moving Into the Future: Comprehensive Management of Crohn’s Disease with IL ...

(Clinical Gastroenterology and Hepatology) Sexual and gender minority individuals with Crohn's disease and ulcerative ... can benefit from mirikizumab (Omvoh) after ustekinumab (Stelara) failure.

which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical and ...

Successful clinical trials and international approvals, such as for the drug Omvoh for Crohn's disease and Ebglyss for atopic dermatitis, further resulted in positive sentiment. These concerted ...

The same candidate is also planning a phase 2b trial in Crohn’s disease as a monotherapy treatment ... In October 2023, the FDA approved Omvoh (mirikizumab), an interleukin-23 antagonist ...

Omvoh could carve a niche for itself in the Crohn's disease market. Ebglyss should also be able to rack up success in treating atopic dermatitis. I expect sales for Alzheimer's disease drug ...

After Hongkong Ban, US Initiates Inquiry Into Indian Spice Products Amid Pesticides Concerns- Check Details. Woman Dies After Taking Ozempic To Look Slim For D ...